Neurodegeneration Flashcards
(158 cards)
1
Q
Neurodegenerative disease include:
A
Alzheimer's Parkinson's Huntington's ALS/MND Spinal muscular atrophy Creutzfeldt-Jakob Multiple sclerosis Other dementias
2
Q
Protein aggregates in diseases are:
A
beta amyloid plaques
TAU tangles
alpha synuclein
TDP43
3
Q
The most common cause of dementia is..
A
Alzheimer’s (62%)
4
Q
Other dementias are..
A
vascular
mixed - AD/vascular
dementia with Lewy bodies
fronto-temporal lobe
5
Q
Alzheimer’s mostly develops after the age of..
A
65
6
Q
AD is not inherited but people with … have a higher risk. Why?
A
Down’s syndrome. They have 3 copies of APP (AD gene)
7
Q
Genes predisposing AD are..
A
APP (amyloid precursor protein), APOE4 (carriers show more beta amyloid), PSEN1 and PSEN2 which encode components of the amyloid pathway.
8
Q
The early symptoms of AD are:
A
Memory lapse due to damage in the hippocampus.
Problem-solving skills.
Language skills.
Visuospatial skills.
9
Q
Other AD symptoms which can be subtle are:
A
inattentiveness cognitive dulling emotional withdrawal (apathy) agitation anxiety
10
Q
Symptoms in later stages of AD become more … and include..
A
Severe:
delusions/hallucinations
dyspraxia
11
Q
Pathologies in AD:
A
Cerebral atrophy Neurofibrillary tangles Plaques Cerebral amyloid angiopathy Gliosis
12
Q
Pathologies of AD are staged by
A
Braak staging
13
Q
B amyloid plaques can reside… They are detectable by..
A
In a neuron or diffuse extracellularly. IHC and silver stains
14
Q
Neuritic plaques are surrounded by..
A
dystrophic cell body projections which label with TAU protein
15
Q
Amyloid is thought to cause..(3)
A
induce neuronal death by apoptosis.
cause oxidative damage.
dysregulate Ca levels - injurying organelles.
16
Q
Amyloid’s effect on neuronal circuits could develop before..
A
cells are lost (ex vivo rat shows synaptic loss as a response to amyloid levels)
17
Q
TAU tangles are found..
A
found with plaques (normal ageing) and are intracellular
18
Q
TAU tangles are seen in which diseases:
A
AD, FTDP, coriticobasal degeneration and Pick’s disease.
19
Q
amyloid angiopathy is… and can cause..
A
amyloid deposition in blood vessels which cause cerebral haemorrhage
20
Q
PSEN mutations cause…important for..
A
lysosomal dysfunction by changing the pH of lysosomes. Involved in autophagy.
21
Q
In AD, mutations in … affect motor proteins from attaching cargo
A
GSK
22
Q
Braak staging shows..
A
spatiotemporal pattern of degeneration
23
Q
in AD, degeneration of the cerebrum usually starts in the..
A
temporal and parietal lobes. Other variants include visual - posterior occipito-parietal/temporal areas
24
Q
25% of AD patients develop..
A
Parkinsonism
25
AD can be mistaken for: (6)
```
Major depression
Cerebrovascular disease
Inflammatory/metabolic disorders
Changes to medial temporal due to infection or vascular insults
Stroke
Tumour
```
26
Current therapies targeting amyloid in AD..
have failed to stop cognitive deficits despite reduction in amyloid.
27
Ways of looking into pathogenesis are:
GWAS, immune system pathway mapping, cholestrol metabolism , synaptic dysfunction and TREM2 variants (microglia and inflammation).
28
3 major therapies used in AD currently are...
AChE inhibitors
NMDAr antagonists
Amyloid targets
29
ACh inhibs cause ... in AD
increase ACh levels to stabilise cognitive function, mainly lost from the nucleus basalis of Meynert (Aricept)
30
NMDAr antagonists are .. and cause..
anti-glutamate drugs which slow progression by reducing Ca, mitochondrial dysfunction and oxidants (Memantine)
31
2 monoclonal antibodies used in AD to target beta amyloid:
Aducanumab
| Solanezumab
32
Aducanumab is a human antibody which has..
a high affinity for aggregated forms. Shown success by reducing neuronal death (through microglia).
33
Solanezumab is a humanised antibody which has a higher affinity for ... than...
Soluble monomeric forms rather than aggregated forms. In phase 3 trials but doesnt show many benefits.
34
Verubecestat in AD is a small molecule which targets..
BACE1 and BACE2, amyloid production pathway. Phase2/3 trials but show low efficiency
35
A core CSF biomarker for AD is...and shows
Abeta42. shows total tau, cortical amyloid deposition
36
temporal lobe lesions affect..
```
hearing
language
object recognition
memory
limbic system
```
37
Motor neurons travel from .. to..
Run from the brain, through the brainstem and spinal cord, and innervate effector muscles
38
Cell bodies of motor neurons are within..
the brain or spinal cord
39
Complex networks of motor neurons develops in... and...
In the embryo and do not get replaced
40
Motor neurons is caused by..in what tract
motor neurons die, muscles stop receiving signals from the brain and waste away.
Corticospinal tract.
41
MND involves degeneration of ... and ... which cause either...
UMN - motor cortex
LMN - anterior horns of spinal cord
Bulbar neurons - motor nuclei
UMN primarily causes lateral sclerosis. LMN cause muscular atrophy.
42
MND is associated with other diseases:
FTD
cognitive problems
Parkinsonism
oculomotor pathologies
43
MND affects ... in the UK. and has a life expectancy of...
5000 people in the UK. Life expectancy of 2-4 years, can be up to 10 but rare.
44
Usual onset of MND is..
60-80 years, but all ages can be affected
45
Death from MND happens due to..
respiratory failure
bulbar dysfunction
bronchopneumonia
46
...% of MND is genetic. Genes are.. and are involved in 3 aspects..
```
10%. C9ORF - intron expansion.
SOD1
TARDBP
FUS
protein homeostasis, RNA binding proteins and cytoskeletal proteins
```
47
Early symptoms of MND:
general weakness of limbs (75%).
Bulbar muscles - medulla (20%).
Respiratory onset (5%)
48
Symptoms of upper MND:
weakness and spasticity - constantly contracted and stiff.
49
Symptoms of lower MND:
weakness due to wasting of muscle and fasiculations - floppy limb
50
Symptoms of bulbar onset (MND):
slurred speech, dysphagia, jaw spasms, tongue fasiculations, teeth grinding
51
In MND, protein inclusions of...are seen in..
TDP43 seen in nuclei and neurofilaments
52
In mutant SOD1 (MND), mitochondria is seen to accumulate..and are also..
in cell bodies instead of along the axon. Seen with vacuoles and swelling in dendrites
53
Mutations affecting axonal transport in MND are...and leads to..
in dynactin complex components. This leads to build up of toxic waste
54
Intronic expansion mutations of C9ORF in MND show..
intra-nuclear RNA foci and cytoplasmic inclusions of p62 - ubiquitin binding protein. Inactivation causes abnormal microglia
55
MND patients with mutations of SOD1 and Fus are distinct because..
they show inclusions of abnormal SOD1 and Fus proteins since they fail to fold properly
56
Treatment for MND works by..eg..
reducing excitation and glutamate - Riluzole
57
Improving survival in later stages of MND is done by..
non-invasive ventilation - tube through trachea
58
Treatments in clinical trials for MND are..
antisense oligonucleotides and monoclonal antibodies through lumbar puncture
59
Current studies for MND..
iPSCs used in drug screens to study toxic glial cells by converting fibroblasts to neural progenitors.
60
What is spinal muscular atrophy?
Recessive motor neuron disease typically in infants.
61
What is mutated in spinal muscular atrophy?
SMN1 gene; SMN protein is not produced
62
In Spinal muscular atrophy, SMN2 is being overexpressed by ... to cause...
antisense oligonucleotide called Nusinersen. This affects splicing of SMN2 so more SMN protein is made. It is administered by lumbar puncture.
63
Other ways of increasing SMN expression in SMA...
Antibodies
| Viral vectors
64
Loss of ... is seen in the spinal cord in MND
white matter
65
Gene silencing of SOD1 is being studied through..
using viral vectors, adenovirus. This can cross the BBB
66
Parkinson's is characterised by neuronal loss in... which causes..
the substantia nigra. Reduces levels of dopamine
67
symptoms of Parkinson's develop after..
80% of neurons are lost
68
general symptoms of Parkinson's are..
stiffness, slow movements and tremors.
69
Other symptoms of PD are:
```
brady/akinesia.
small-stepped gait.
stooped posture.
reduced arm swing.
repeated movements.
tremor at rest
rigidity - dull ache
```
70
Parkinson's tremor has features of..
present at rest and unilateral
71
Later staged symptoms of PD are:
```
on/off dyskinesia.
choreiform movements (jerky).
depression.
dementia.
anxiety.
hallucinations.
constipation.
urinary incontinence
```
72
conditions with similar symptoms to PD are:
Normal pressure hydrocephalus - corrected by draining of CSF.
Essential tremor in the elderly - not at rest and no increased tone
73
Pathology of substantia nigra in Parkinson's shows..
cell loss and Lewy bodies of a synuclein.
| TDP43 deposits in nuclei.
74
Risk factors of PD are genetic and enrivonmetal. Toxins from pesticides such as MPTP have shown to ... in dopaminergic neurons
inhibit Cl- channels - Cl- cant move in, can't repolarise
75
Imaging has shown the mitochondrial network in PD is..
hyperfused, meaning lower activity of mitochondria
76
PINK and Parkin are regulators of..
mitophagy - degradation of mitochondria.
77
Loss of PINK1 generally causes..
mitochondrial dysfunction and increased sensitivity to oxidative stress.
78
PINK is normally degraded constantly. When mitochondria are non-functional...
PINK phosphorylates Parkin and ubiquitin on mitochondrial membranes. This prevents mitophagy.
79
LRRK2 mutants in PD inhibit..
autophagy
80
Main treatments for PD focus on..
compensating the loss of dopamine
81
The 3 types of dopamine treatment are:
LDOPA
Dopamine agonists
COMT/MAO-B inhibitors
82
Anti-cholinergics are also used in PD to..
reduce excitation in tremors. Not good, have side effects on cognition
83
L-DOPA is...and how is it taken?
the precursor of dopamine. It comes in 3 different preparations:
kick start morning
release throughout day
slow release at night
84
Dopamine agonists such as Ropinirole, Praipexole and Rotigotine are used as..
substitues for dopamine, targeting postsynaptic dopamine receptors. They are a first choice drug when treating younger patients (under 60).
85
MAO-B and COMT inhibitors both inhibit..
enzymes which breakdown dopamine - catechol-o-methyl-transferase and monoamino-oxidase (also ALDH).
86
Gene therapies in PD aim to...and use lentivirus to deliver..
replace dopamine. Lentivirus delivers tyrosine hydroxylase - enzyme which converts L-tyrosine to L-DOPA. Tested in small and large animals, and injected into putamen of Parkinson's patients.
87
Oxidative stress pathway has been targeted in PD by..which targets..
Small molecules target the Nrf2/ARE pathway, activating protection against oxidative stress in neuronal cultures.
88
Long term medication in PD causes..
wearing off effect - on/off phases of dyskinesia
89
Huntington's causes death .... after onset
15-20 years
90
the HD gene htt is..
located on chromosome 4 and is a trinucleotide polyglutamate repeat disorder (CAG)
91
Huntington's is a ... inherited disease of..
monogenic, autosomal dominant - passed on from either parent. Severe atrophy of the striatum and cortex.
92
Normal amount of CAG repeat is ... too many causes what in HD?
35 repeats. Over 40 repeats cause over-production of huntingtin protein.
93
Age of onset of HD is.. correlates to..
30-50 years. number of CAG repeats
94
Regional patterning of huntingtin is mainly seen in..
the striatum but also in cortex
95
Physical symptoms of HD are:
Chorea - progressive.
Dystonia - fixed posture.
Myoclonus - jerky
Tics
96
Other symptoms of HD are:
Cognitive impairments:
slowness of thoughts.
apathy.
subcortical dementia
97
Chorea in HD occurs due to..
loss of inhibitory GABA neurons in basal ganglia; dopaminergic neurons more active causing movement
98
Pathologies seen in HD:
Atrophy of cerebrum, sulci and caudate nucleus.
Astrogliosis - vast proliferation.
Reduced astrocyte response to amyloid
Protein aggregates
99
Protein aggregates seen in Huntington's are:
TAU
Beta amyloid
Alpha synuclein
Huntingtin
100
Expansions of trinucleotide repeats cause... Common expansions are..
Gain of function, autosomal dominant effects. Found in promoters, UTRs, introns and exons. Common repeats are polyglutamine and polyalanine.
101
Post mortem tissue of HD has shown abnormal..
mitochondrial morphology; less cristae, with prominent defects in CII, changes in mtDNA and Ca handling.
102
Mice with mutant htt have shown..
localisation of htt on outer mitochondrial membranes with CII defects and reduced O2 consumption. This correlates to CAG repeat length.
103
JNK is mutated in HD. It is an abnormally active...involved in..
Kinase involved in regulation of phosphorylation of kinesin and dynein activity.
104
It is thought that Htt has roles in:
```
Transcriptional regulation.
Protein homeostasis.
Oxidative stress.
Axonal transport.
Synaptic transmission
Suppression of apoptosis
```
105
HD is treated by..
Antipsychotics: presynaptic release of dopamine, postsynaptic receptor activation.
Interference of vesicle storage. Tetrabenazine
106
Tetrabenazine works by reducing..
uptake of dopamine by presynaptic vesicles and depleting dopamine storage.
107
Tetrabenazine is not great as..
not a lot of improvement.
| Many adverse effects - sedation, depression, anxiety, insomnia
108
Sulpiride, Olanzapine, Haloperidol work in HD as...
dopamine receptor antagonists to reduce abnormal movement
109
Dystonia (abnormal tone and posture) can be alleviated by..
Botulinum toxins and Clonazepam
110
Trials in HD are targeting mutant htt protein with..
small molecules and antisense oligonucleotides
111
Microglia are immune cells of the CNS. They make up...of the CNS and have ... origin
1-15%. Originate from myeloid lineage (not neuronal).
112
Microglia respond in... and indicate..
a sensitive but non-specific way. They are pathological markers for disease
113
Features of TDP43 are..
amorphous, disordered, and have prion-like domains
114
Prions are..and have ...formation
RNA binding proteins which self replicate and transmit disease. They form an amyloid fibril-like formation.
115
Lewy body dementia has symptoms of..
Fluctuating cognitive decline.
Visual hallucinations.
Parkinsonism.
Neuroleptic sensitivity.
116
In Lewy body dementia, Lewy bodies are found... and are made of..
neurons of neocortex, limbic system and brainstem.
| They are made of alpha synuclein
117
Vascular dementia is caused by..
infarcts in small or large vessel. Dementia is dependent on the location of infarct.
118
Risk factors of vascular dementia are..
atherosclerosis; smoking, alcohol, hypertension, cardiac disease, diabetes and genetics.
119
Gliosis is..and can lead to..
proliferation of several types of glial cells (astrocytes, microglia and oligodendrocytes). Can lead to scarring
120
Astrocytes provide..
trophic support to neurons and show response to damage
121
Astrocytes expressing SOD1 mutations in MND are..
selectively toxic to motor neurons by releasing factors.
122
Glial cells expressing mutant htt in HD have reduced..
ability to protect htt mutated neurons
123
Microglia respond to damage by..which causes..
retracting and thickening their processes. They form a rounded amoeboid-like shape, and express different molecules to induce astrocytes.
124
Microglia have 3 states:
M0 - resting
M1 - active, toxic
M2 - active, wound healing
125
Neurodegenerative diseases are characteristed by clumps of ... proteins. This also means there is reduced..
Ubiquinated. There is reduced function of ubiquitin proteasome systems
126
Protein inclusions start in specific areas due to selective vulnerability, and spread..how..
through the brain in a stepwise fashion, correlating with disease progression
127
Selective vulnerability in AD is in..
entorhinal cortical and hippocampal CA1 neurons. These are particularly vulnerable to energy deprivation.
128
Selective vulnerability in HD is in..
spiny striatal neurons which express Cav1.3 channels; mediate Ca influx
129
Selective vulnerability in MND is in...
Spinal motor neurons are prone to hyperexcitation as they have low expression of GABA receptors. They express Cav1.3 channels which mediate Ca influx
130
Pathology is thought to spread throughout the brain by..
affected neurons produce toxins, picked up by surrounding neurons.
OR areas get affected in turn
131
Amyloid fibril formations have the ability to recruit other proteins to become amyloidogenic in order to build what structure?
twisted, non-branching filaments of beta sheets. Structures are fibrillar or multimeric.
132
Spread of aggregates requires neurons to..
release and uptake from other neurons. May occur by secretory/endocytic pathways or across synapses.
133
TAU, alpha synuclein and TDP43 can be transported to other neurons how?
Through the axon antero/retrogradely. Seen through in vitro studies.
134
Injection of TAU or synuclein into the brain causes aggregates where?
in anatomical structures distant from site of injection, implying that neuronal connections are involved in spread of aggregates.
135
Recent studies have shown TAU, beta amyloid and synuclein have different conformational variants which show different...
seeding properties and different levels of neurotoxicity. This contributes to heterogeneity of neurodegen diseases.
136
Evidence to suggest that protein aggregates are toxic are..
Proteins are mutated in familial diseases
137
Evidence suggesting protein aggregates are not toxic is..
model organism studies have shown toxicity in the absence of aggregates, suggesting they may be protective.
138
Longer protein aggregates have a slower turnover which potentially..
overwhelms protein homeostasis and degradation pathways
139
Aggregates interact with other molecules, and can ... other proteins
sequester. This affect transcription.
140
Aggregates interfere with what processes?
Axonal transport
| Nucleocytoplasmic
141
In MS, remyelination of oligodendrocytes has been looked at through
stem cell screening
142
Mitochondrial dysfunction affects..
Glucose and oxygen supply.
| Ca handling
143
Lysosomal degradation pathway is activated in cells in response to stresses:
when a cell is starved.
When damaged constituents are present (eg. aggregates).
To defend themselves from pathogens
144
Autophagy is regulated by..
basal turnover and stress responses
145
mTOR activity in autophagy is regulated by signals of:
```
nutrients.
Growth factors.
stress pathways
energy pathways
Inositol pathways
cAMP, Ca and JNK pathways
```
146
In neurodegen diseases, autophagy is observed as dysfunctional as..
protein aggregates are tagged with ubiquitin but are not apoptosed
147
p62 is a receptor for ... which is seen to be defective in neurodegen diseases.
autophagosomes
148
Knockouts in mice have shown that loss of essential autophagy proteins cause..
accumulation of aggregates and neuronal loss. Neurons are sensitive to loss of autophagy
149
Autophagy has been stimulated by ... called rapalogs. These are inhibitors of...
small molecules which are inhibitors of mTOR
150
Axonal transport works by components:
microtubules
Kinesin
dynein
151
molecular motors work as..
ATPases, converting chemical energy to mechanical energy
152
Dynein has other chains which bind to..
cargo and dynactin - factor for cargo binding
153
Fast axonal transport is for..
synaptic vesicles and mitochondria (50-400mm/day)
154
Slow axonal transport pauses between movements and moves..
proteins and larger molecules
155
Abnormal and excessive activation of kinases in motor proteins are hallmarks of neurodegen diseases. EG:
```
p38
MAPK
JNK
GSK
(In AD, MNS and HD)
```
156
Kinase mutations phosphorylate kinesin and dynein. Mutations cause mitochondria to...kinesin to be..and prevent cargo...
cluster around the nucleus.
| Kinesin is released from microtubules (preventing transport). Prevents cargo from attaching to motor proteins.
157
When ...... are mutated, it causes microtubules to become unstable, reducing transport
TAU, Spastin and Hsps
158
Gene therapy involves the use of... to carry genes or molecules
vectors: plasmids, nanoparticles, viral - lentiviral or adenoviral
